Supplemental File 3.

Study details

Author	Comparative therapy	Design	Duration of follow-up (months)	Sample size (eyes)	Dosing interval
Bahrami, et al., 201925	None	Interventional (clinical trial)	11	41	2q8
Campos Polo, et al., 201846	None	Interventional (clinical trial)	12	29	2q8
Terasaki et al., 201917	None	Interventional (clinical trial)	12	72	2q8
Garweg et al., 201923	None	Interventional (clinical trial)	12	553	2q8
Pak et al., 202037	None	Interventional (clinical trial)	12	46	Treat and extend
Curry et al., 202032	None	Interventional (clinical trial)	24	26	Treat and extend
Kaiho et al., 201733	None	Retrospective case series	12	51	Every 4 weeks for 1-3 loading injections then PRN
Lukic et al., 202047	None	Retrospective case series	12	99	Every 4 weeks for 5 loading injections then PRN
McCloskey, et al., 201815	None	Retrospective case series	24	18	N/A
Tsapardoni et al., 201916	None	Retrospective case series	24	30	2q8 in 1st year, treat-and-extend in 2nd year
Kern et al., 202048	None	Retrospective case series	24	139	Every 4 weeks for 3 loading injections then PRN
Khattab et al., 201918	Nonea	RCT	18	27 (in aflibercept monotherapy)	Every 4 weeks for 3 loading injections then PRN
Abouhussein and Gomaa, 202031	Nonea	RCT	12	20 (in aflibercept monotherapy)	Every 4 weeks for 3 loading injections then PRN
Do et al., 201230	Laser photocoagulation	RCT	12	0.5q4: 38, 2q4: 33, 2q8: 34, 2PRN: 38, laser: 33	0.5q4, 2q4, 2q8, PRN
Chen et al., 202027	Laser photocoagulation	RCT	12	Aflibercept 2q4: 122, 2q8: 116, laser: 117	2q4 or 2q8
Korobelnik et al., 201429	Laser photocoagulation	RCT	12	Combinedb: Aflibercept, 2q4: 290, 2q8: 286, laser: 286	2q4 or 2q8
Brown et al., 201528	Laser photocoagulation	RCT	23	Combinedb: Aflibercept, 2q4: 291, 2q8: 287, control: 287	2q4 or 2q8
Baker et al., 201926	Laser photocoagulation	RCT	24	Aflibercept: 226, laser: 240, observation: 236	PRN
Heier et al., 201619	Laser photocoagulation	RCT	34	Combinedb: Aflibercept, 2q4: 291, 2q8: 287, laser: 287	2q4 or 2q8
Ozsaygili and Duru, 202022	Dexamethasone	RCT	12	Aflibercept: 50, dexamethasone: 48	Every 4 weeks for 3 loading injections then PRN
Hernández-Bel et al., 201934	Dexamethasone/aflibercept dual therapya	Retrospective cohort study	12	Aflibercept: 15, dexamethasone: 15	2q8
Kaldırım, et al., 201920	Ranibizumab	Prospective cohort study	12	Aflibercept: 30, ranibizumab: 30	Every 4 weeks for 3 loading injections then PRN
Bhandari et al., 202038	Ranibizumab	Prospective cohort study	12	Aflibercept: 217, ranibizumab: 166	PRN
Ozkaya, et al., 202021	Ranibizumab	Retrospective cohort study	12	Aflibercept: 20, ranibizumab: 26	Every 4 weeks for 3 loading injections then PRN
Plaza-Ramos et al., 201936	Ranibizumab	Retrospective cohort study	12	Aflibercept: 91, ranibizumab: 122	Every 4 weeks for 3 loading injections then PRN
Schwarzer, et al., 201949	Ranibizumab	Retrospective cohort study	12	Aflibercept: 34, ranibizumab: 41	Treat and extend (average every 5.9 weeks)
Fouda and Bahgat, 201735	Ranibizumab	RCT	12	Aflibercept: 35, ranibizumab: 35	Every 4 weeks for 3 loading injections then PRN
Ciulla, et al., 201850	Ranibizumab and bevacizumab	Retrospective cohort study	24	12-months cohort Aflibercept: 1379, bevacizumab: 3109, ranibizumab: 1352 24-months cohort Aflibercept: 800, bevacizumab: 2403, ranibizumab: 1952	N/A
Wells et al., 20155	Ranibizumab and bevacizumab	RCT	12	Aflibercept: 208, bevacizumab: 206, ranibizumab: 206	2q4
Wells et al., 201624	Ranibizumab and bevacizumab	RCT	24	Aflibercept: 201, bevacizumab: 185, ranibizumab: 192	2q4 for 1 year, then PRN

^aOnly results relating to the aflibercept arm were considered, ^bThis study evaluated a combined database (VIVID and VISTA). 2q4: 2 mg every 4 weeks, 2q8: 2 mg every 8 weeks, 0.5q4: 0.5 mg every 4 weeks, PRN: Pro-re-nata (as needed), RCT: Randomized controlled trial, NA: Not available